Patents by Inventor David S. J. Allan
David S. J. Allan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240024479Abstract: Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express a thrombopoietin receptor, an erythropoietin receptor, or a chimeric polypeptide including an extracellular domain of a thrombopoietin receptor, a transmembrane domain, and an intracellular domain including an interleukin-2 receptor beta intracellular signaling domain. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.Type: ApplicationFiled: October 3, 2023Publication date: January 25, 2024Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, David S.J. Allan
-
Publication number: 20230089654Abstract: Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some embodiments, the NK cells or T cells express a thrombopoietin receptor or an erythropoietin receptor. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.Type: ApplicationFiled: August 23, 2022Publication date: March 23, 2023Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, David S.J. Allan, Chantiya Chanswangphuwana
-
Publication number: 20220228117Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.Type: ApplicationFiled: March 7, 2022Publication date: July 21, 2022Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, David S.J. Allan
-
Patent number: 11293010Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.Type: GrantFiled: November 1, 2017Date of Patent: April 5, 2022Assignee: The United States of America, as represented by the Secretary, Department and of Health and Human ServicesInventors: Richard W. Childs, David S. J. Allan
-
Publication number: 20200392457Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.Type: ApplicationFiled: November 1, 2018Publication date: December 17, 2020Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, David S.J. Allan
-
Publication number: 20180057795Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.Type: ApplicationFiled: November 1, 2017Publication date: March 1, 2018Inventors: Richard W. Childs, David S.J. Allan
-
Publication number: 20150361180Abstract: The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.Type: ApplicationFiled: April 10, 2015Publication date: December 17, 2015Applicant: ISIS INNOVATION LIMITEDInventors: Veronique M. Braud, David S.J. Allan, Graham S. Ogg, Christopher A. O'Callaghan, Andrew J. McMichael
-
Publication number: 20080274475Abstract: The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.Type: ApplicationFiled: April 25, 2008Publication date: November 6, 2008Applicant: ISIS INNOVATION LIMITEDInventors: Veronique M. Braud, David S.J. Allan, Graham S. Ogg, Christopher A. O'Callaghan, Andrew J. McMichael
-
Patent number: 7410767Abstract: The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.Type: GrantFiled: December 4, 1998Date of Patent: August 12, 2008Assignee: Isis Innovation LimitedInventors: Veronique M. Braud, David S. J. Allan, Graham S. Ogg, Christopher A. O'Callaghan, Andrew J. McMichael